These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


151 related items for PubMed ID: 8271535

  • 1. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
    Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, Kawai C.
    Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
    [Abstract] [Full Text] [Related]

  • 2. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
    Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, Kawai C.
    Jpn J Pharmacol; 1993 Nov; 63(3):319-25. PubMed ID: 8107325
    [Abstract] [Full Text] [Related]

  • 3. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Mizuo H, Yuzuriha T, Yui Y, Kawai C.
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [Abstract] [Full Text] [Related]

  • 4. YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi.
    Suzuki M, Funatsu T, Tanaka H, Usuda S.
    Jpn J Pharmacol; 1998 Jul; 77(3):177-83. PubMed ID: 9717764
    [Abstract] [Full Text] [Related]

  • 5. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator.
    Kawasaki T, Kawamura S, Katoh S, Takenaka T.
    Jpn J Pharmacol; 1993 Oct; 63(2):135-42. PubMed ID: 8283822
    [Abstract] [Full Text] [Related]

  • 6. Thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator, in a photochemically induced platelet-rich thrombosis model.
    Kawasaki T, Kaku S, Takenaka T, Yanagi K, Ohshima N.
    J Cardiovasc Pharmacol; 1994 Jun; 23(6):884-9. PubMed ID: 7523779
    [Abstract] [Full Text] [Related]

  • 7. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ, Follenfant MJ, Ford AJ.
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [Abstract] [Full Text] [Related]

  • 8. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ, Wu ZM, Stassen T, Van de Werf F, Collen D.
    Blood; 1990 Oct 15; 76(8):1558-63. PubMed ID: 2119830
    [Abstract] [Full Text] [Related]

  • 9. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
    Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Yui Y, Kawai C.
    J Cardiovasc Pharmacol; 1993 Dec 15; 22(6):834-40. PubMed ID: 7509901
    [Abstract] [Full Text] [Related]

  • 10. Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.
    Kawasaki T, Kaku S, Sakai Y, Takenaka T.
    J Pharm Pharmacol; 1996 Oct 15; 48(10):1041-8. PubMed ID: 8953506
    [Abstract] [Full Text] [Related]

  • 11. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR, Wu Z, Pauwels P, Lijnen HR, Collen D.
    J Am Coll Cardiol; 1992 May 15; 19(6):1350-9. PubMed ID: 1342779
    [Abstract] [Full Text] [Related]

  • 12. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep 15; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 13. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
    Yokoyama M, Ichikawa Y, Yatani A, Matsui K, Nakahara H, Kaneko M, Sakurama T, Ueshima S, Matsuo O.
    J Cardiovasc Pharmacol; 1996 Oct 15; 28(4):571-5. PubMed ID: 8891884
    [Abstract] [Full Text] [Related]

  • 14. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
    Martin U, Sponer G, König R, Smolarz A, Meyer-Sabellek W, Strein K.
    Blood Coagul Fibrinolysis; 1992 Apr 15; 3(2):139-47. PubMed ID: 1606285
    [Abstract] [Full Text] [Related]

  • 15. Newer thrombolytic agents.
    Verstraete M.
    Ann Acad Med Singap; 1999 May 15; 28(3):424-33. PubMed ID: 10575530
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U, Sponer G, Strein K.
    J Am Coll Cardiol; 1992 Feb 15; 19(2):433-40. PubMed ID: 1732372
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
    Cambier P, van de Werf F, Larsen GR, Collen D.
    J Cardiovasc Pharmacol; 1988 Apr 15; 11(4):468-72. PubMed ID: 2453751
    [Abstract] [Full Text] [Related]

  • 18. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
    Suzuki N, Suzuki S, Nagaoka N, Mizuo H, Yuzuriha T, Yoshitake S, Kanmatuse K.
    Jpn J Pharmacol; 1994 Jul 15; 65(3):257-63. PubMed ID: 7799526
    [Abstract] [Full Text] [Related]

  • 19. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR, Lijnen HR, Stassen JM, Collen D.
    Blood; 1991 Jul 01; 78(1):125-31. PubMed ID: 1906351
    [Abstract] [Full Text] [Related]

  • 20. Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi.
    Suzuki M, Asano H, Kimoto A, Tanaka H, Usuda S.
    J Pharm Pharmacol; 2000 Aug 01; 52(8):969-76. PubMed ID: 11007068
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.